DermTech (NASDAQ:DMTK) Downgraded by Zacks Investment Research to Sell

DermTech} stock has undergone multiple analysts rating changes in the recent past.  DermTech Downgraded by Zacks Investment Research on 10/20/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More DermTech (NASDAQ:DMTK) Downgraded by Zacks Investment Research to Sell

Earnings Report: Here’s what to expect from DermTech (NASDAQ:DMTK)

Earnings results for DermTech , Analyst Opinion on DermTech , Earnings and Valuation of (NASDAQ:DMTK), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings Report: Here’s what to expect from DermTech (NASDAQ:DMTK)

Earnings and Growth Analysis : DermTech (NASDAQ:DMTK)

Earnings results for DermTech , Analyst Opinion on DermTech , Earnings and Valuation of (NASDAQ:DMTK), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings and Growth Analysis : DermTech (NASDAQ:DMTK)

Reports Strong First-Quarter Financial Results DermTech (NASDAQ:DMTK)

Earnings results for DermTech , Analyst Opinion on DermTech , Earnings and Valuation of (NASDAQ:DMTK), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Reports Strong First-Quarter Financial Results DermTech (NASDAQ:DMTK)